David Chen

5.4k total citations · 2 hit papers
75 papers, 3.6k citations indexed

About

David Chen is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, David Chen has authored 75 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 22 papers in Molecular Biology and 20 papers in Oncology. Recurrent topics in David Chen's work include Renal cell carcinoma treatment (19 papers), Cancer Genomics and Diagnostics (13 papers) and Bladder and Urothelial Cancer Treatments (11 papers). David Chen is often cited by papers focused on Renal cell carcinoma treatment (19 papers), Cancer Genomics and Diagnostics (13 papers) and Bladder and Urothelial Cancer Treatments (11 papers). David Chen collaborates with scholars based in United States, Canada and Switzerland. David Chen's co-authors include José Baselga, Sarat Chandarlapaty, Gabriel N. Hortobágyi, Maurizio Voi, Michael F. Berger, Zhiqiang Li, Weiyi Toy, Kinisha Gala, Sean W. Fanning and Tetiana Taran and has published in prestigious journals such as Nature, The Lancet and Journal of Clinical Investigation.

In The Last Decade

David Chen

74 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

2013 855 citations David Chen et al. profile →
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

2013 629 citations John J. Bissler, J.C. Kingswood et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Chen United States	25	1.5k	1.4k	1.4k	877	606	75	3.6k
Ramaprasad Srinivasan United States	35	2.5k 1.7×	3.0k 2.1×	818 0.6×	1.6k 1.8×	245 0.4×	131	4.6k
Lisa G. Horvath Australia	46	2.5k 1.7×	2.4k 1.7×	2.2k 1.6×	1.6k 1.9×	159 0.3×	198	6.0k
Joseph Boni United States	28	1.4k 0.9×	2.5k 1.7×	1.8k 1.3×	822 0.9×	181 0.3×	88	4.7k
Paresh Vyas United Kingdom	52	406 0.3×	4.4k 3.1×	1.3k 1.0×	899 1.0×	608 1.0×	235	9.4k
Katsumasa Kuroi Japan	32	521 0.4×	869 0.6×	2.2k 1.6×	1.3k 1.4×	425 0.7×	143	3.8k
Zhong Jiang United States	42	1.8k 1.2×	2.2k 1.5×	794 0.6×	1.2k 1.4×	175 0.3×	129	4.6k
Wendy A. Cooper Australia	35	2.9k 2.0×	2.0k 1.4×	2.5k 1.8×	1.4k 1.5×	301 0.5×	131	5.7k
Jason Gotlib United States	51	1.0k 0.7×	4.0k 2.8×	1.3k 0.9×	480 0.5×	616 1.0×	297	11.0k
Chin‐Chen Pan Taiwan	33	997 0.7×	951 0.7×	595 0.4×	422 0.5×	227 0.4×	100	2.8k
Daniel Rosen United States	37	421 0.3×	2.6k 1.9×	1.5k 1.1×	1.0k 1.1×	218 0.4×	87	4.9k

Countries citing papers authored by David Chen

Since Specialization

Citations

This map shows the geographic impact of David Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Chen more than expected).

Fields of papers citing papers by David Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Chen. The network helps show where David Chen may publish in the future.

Co-authorship network of co-authors of David Chen

This figure shows the co-authorship network connecting the top 25 collaborators of David Chen. A scholar is included among the top collaborators of David Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Chen. David Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tran, Hanh, Ian T. MacQueen, David Chen, & M. P. Simons. (2023). Systematic Review and Guidelines for Management of Scrotal Inguinal Hernias. SHILAP Revista de lepidopterología. 2. 11195–11195. 11 indexed citations

Dziadziuszko, Rafał, Matthew Krebs, Filippo de Braud, et al.. (2021). Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticROS1Fusion–Positive Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 39(11). 1253–1263. 111 indexed citations

Masic, Selma, Marshall Strother, Brian L. Egleston, et al.. (2021). Feasibility and Outcomes of Renal Mass Biopsy for Anatomically Complex Renal Tumors. Urology. 158. 125–130. 3 indexed citations

Geraci, Travis C., David Chen, Amie J. Kent, et al.. (2021). Beyond the learning curve: a review of complex cases in robotic thoracic surgery. Journal of Thoracic Disease. 13(10). 6129–6140. 8 indexed citations

Riquelme, Sebastián A., Tania Wong Fok Lung, Blanche L. Fields, et al.. (2020). Pseudomonas aeruginosa Utilizes Host-Derived Itaconate to Redirect Its Metabolism to Promote Biofilm Formation. Cell Metabolism. 31(6). 1091–1106.e6. 132 indexed citations

Hsu, Chao‐Jung, et al.. (2019). Error variability affects the after effects following motor learning of lateral balance control during walking in people with spinal cord injury. European Journal of Neuroscience. 50(8). 3221–3234. 8 indexed citations

Chen, David, et al.. (2018). A novel technique for tracheal reconstruction using a resorbable synthetic mesh. The Laryngoscope. 128(7). 1567–1570. 3 indexed citations

Pavel, Marianne, David Chen, Maurizio Voi, et al.. (2017). Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. Pancreas. 46(6). 751–757. 3 indexed citations

Yao, James C., Marianne Pavel, Catherine Lombard‐Bohas, et al.. (2016). Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. Journal of Clinical Oncology. 34(32). 3906–3913. 192 indexed citations

10.

Xu, Jianing, Can G. Pham, Steven K. Albanese, et al.. (2016). Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. Journal of Clinical Investigation. 126(9). 3526–3540. 77 indexed citations

11.

Zhu, Andrew X., David Chen, Masayuki Kanai, et al.. (2016). Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. Journal of Hepatology. 65(2). 296–304. 24 indexed citations

12.

Voss, Martin H., David Chen, Mahtab Marker, et al.. (2016). Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. British Journal of Cancer. 114(6). 642–649. 36 indexed citations

13.

Shaikh, Talha, Tianyu Li, Elizabeth A. Handorf, et al.. (2016). Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 97(4). 722–731. 34 indexed citations

14.

Huynh, Hung, Huai-Xiang Hao, Stephen L. Chan, et al.. (2015). Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. Molecular Cancer Therapeutics. 14(5). 1224–1235. 60 indexed citations

15.

Kwiatkowski, David J., Michael R. Palmer, Sergiusz Jóźwiak, et al.. (2015). Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. European Journal of Human Genetics. 23(12). 1665–1672. 31 indexed citations

16.

Benlloch, Susana, María Luisa Botero, Clara Mayo, et al.. (2014). Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial. PLoS ONE. 9(2). e89518–e89518. 34 indexed citations

17.

Bissler, John J., J.C. Kingswood, Elżbieta Radzikowska, et al.. (2013). Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 381(9869). 817–824. 629 indexed citations breakdown →

18.

Cohen, R.J., Navesh Sharma, Karen Ruth, et al.. (2011). Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy. Brachytherapy. 11(3). 209–213. 6 indexed citations

19.

Wang, Baohua, Tao Luo, David Chen, & David M. Ansley. (2007). Propofol Reduces Apoptosis and Up-Regulates Endothelial Nitric Oxide Synthase Protein Expression in Hydrogen Peroxide-Stimulated Human Umbilical Vein Endothelial Cells. Anesthesia & Analgesia. 105(4). 1027–1033. 56 indexed citations

20.

Zimmer, Aline, Edward A. Silverstein, Stewart Spies, et al.. (1993). A Phase I Escalating-Dose Safety, Dosimetry and Efficacy Study of Radiolabeled Monoclonal Antibody LYM-1. PubMed. 8(1). 3–16. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact